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ABSTRACT 
The role of inflammation in the development of atherosclerosis is now accepted and a 
focus of many studies because of its complex mechanisms. The risk of cardiovascular 
disease (CVD) and atherosclerosis is reported to be increased in systemic lupus 
erythematosus (SLE), especially in the group of young women. The introduction of 
statins in the 1990
’
s lowered considerably the morbidity and mortality in CVD. In the 
last decade, research efforts were concentrated on the immunological mechanisms of 
atherosclerosis and on the possibility to influence these mechanisms. 
Our group recently reported a negative association between natural IgM-antibodies 
against phosphorylcholine (IgM anti-PC) and CVD outcome in the general 
population. Potential mechanisms considered include anti-inflammatory properties 
and inhibition of uptake of oxidized low density lipoprotein (oxLDL) in 
macrophages. The objective herein was to study mechanisms of atherosclerosis in 
SLE and the relation to traditional and non-traditional risk factors in an SLE cohort, in 
comparison with an age and sex matched control group. As systemic endothelial 
dysfunction is one of the earliest signs of atherosclerosis in the general population, we 
also assessed skin microvascular endothelial function in SLE patients and controls. 
A total of 114 patients with SLE were compared with 122 age and sex-matched 
population-based controls. Common carotid intima-media thickness (IMT), calculated 
intima-media area (cIMa) and plaque occurrence were determined by B-mode 
ultrasound. Plaques were graded according to echogenicity. Anti-PC was assessed by 
enzyme-linked immunosorbent assay (ELISA). Endothelial function in skin was tested 
with local application of acetylcholine (ACh) and any concomitant increase in skin 
perfusion was measured with Laser Doppler Fluxmetry (LDF) in 84 of the SLE-
patients and 81 of the age- and sex-matched controls. 
Incidence of hypertension, presence of insulin resistance (determined by homeostasis 
model assessment of insulin resistance, HOMA-IR) and the levels of triglycerides and 
C-reactive protein (CRP) were increased in the SLE patients, while smoking, 
cholesterol and high density lipoprotein (HDL) did not differ from controls. Low 
levels of IgM anti-PC were more common in the SLE patients than in the controls. 
IMT and cIMa did not differ significantly between groups. However, plaques were 
more often found in the SLE patients. Age, LDL and IgM anti-PC were 
independently associated with plaque occurrence in the SLE patients. Furthermore, in 
the left carotid arteries echolucent plaques were more prevalent in SLE when 
compared to controls. There were no significant differences in skin microvascular 
endothelial function between SLE patients and controls. In the SLE group, 
endothelial function did not vary in relation to presence of skin manifestations, 
Raynaud’s phenomenon, nephritis or plaque occurrence. In SLE patients with CVD, 
however, endothelial function was impaired. 
Conclusion: Plaque occurrence in the carotid arteries was increased in SLE and was 
independently associated with age, LDL and low anti-PC levels. Vulnerable plaques 
were more common in SLE than in controls. Anti-PC could be a novel risk marker for 
atherosclerosis with therapeutic potential in SLE. Skin microvascular endothelial 
function was associated with CVD but not with early signs of atherosclerosis in SLE-
patients. The endothelial function was not different in SLE-patients, as compared to 
controls. 
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1 SYSTEMIC LUPUS ERYTHEMATOSUS  
1.1 INTRODUCTION   
Systemic Lupus Erythematosus (SLE) is an inflammatory, autoimmune disease with 
multiorgan involvement, a wide variety of manifestations and an unpredictable course. 
It is characterized by excessive autoantibody production, immune complex formation 
and immunologically mediated tissue injury. 
 
1.2 HISTORY 
Pierre Louis Alphée Cazenave is credited with the introduction of the term “lupus 
erythematosus”, in 1852. Moriz Kaposi, in 1872, recognized the systemic nature of the 
disease. In the beginning of the 20
th
 century, Emanuel Libman and Benjamin Sacks 
described an endocarditis of a peculiar type in SLE. Paul Klemperer first used the term 
“diffuse connective tissue disease” in 1941. The history of SLE continued with Harris, 
who described in 1987, the Antiphospholipid Syndrome, a disorder that is manifested 
clinically as recurrent venous or arterial thrombosis and/or fetal loss and is 
characterised by antibodies against cardiolipin and beta 2 glycoprotein I. 
 
1.3 CLASIFICATION CRITERIA 
Already in 1971 the American College of Rheumatology proposed 14 criteria to 
diagnose SLE. The list was revised in 1982 and 1997, and currently includes 11 
criteria: malar rash, discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal 
involvement, central nervous system involvement, hematologic abnormalities and 
immunologic markers (Table 1). The presence of at least four criteria is required to 
establish a diagnosis of SLE (Tan et al., 1982, Hochberg, 1997).  
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Table 1. Classification Criteria for the Diagnosis of SLE (Smith and Shmerling, 1999) 
1. Malar rash  Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds  
2. Discoid rash  Erythematous raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scarring may occur in older lesions  
3. Photosensitivity  Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation  
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually painless, observed by physician  
5. Nonerosive Arthritis  Involving 2 or more peripheral joints, characterized by tenderness, swelling, or 
effusion  
6. Pleuritis or Pericarditis  1. Pleuritis--convincing history of pleuritic pain or rubbing heard by a 
physician or evidence of pleural effusion,  
OR  
2. Pericarditis--documented by electrocardiogram or rub or evidence of 
pericardial effusion  
7. Renal Disorder  1. Persistent proteinuria > 0.5 grams per day or > than 3+ if quantitation not 
performed, 
OR  
2. Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed  
8. Neurologic Disorder  1. Seizures--in the absence of offending drugs or known metabolic 
derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance 
OR 
2. Psychosis--in the absence of offending drugs or known metabolic 
derangements, e.g., uremia, ketoacidosis, or electrolyte imbalance  
9. Hematologic Disorder  1. Hemolytic anemia--with reticulocytosis  
2. Leukopenia--< 4,000/mm3 on ≥ 2 occasions  
3. Lymphopenia--< 1,500/ mm3 on ≥ 2 occasions  
4. Thrombocytopenia--<100,000/ mm3 in the absence of offending drugs  
10. Immunologic Disorder  1. Anti-DNA: antibody to native DNA in abnormal titer  
OR  
2. Anti-Sm: presence of antibody to Sm nuclear antigen  
OR  
3. Positive finding of antiphospholipid antibodies on:  
    3. 1. an abnormal serum level of IgG or IgM anticardiolipin antibodies,  
    3. 2. a positive test result for lupus anticoagulant using a standard method, or  
    3. 3. a false-positive test result for at least 6 months confirmed by 
Treponema pallidum immobilization or fluorescent treponemal antibody 
absorption test  
11. Positive Antinuclear 
Antibody  
An abnormal titer of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs  
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1.4 INCIDENCE AND DISEASE COURSE 
The incidence rate is approximately 4 per 100000 person year. The disease is 2 to 4 
times more frequent and more severe among nonwhite populations around the world. 
Men, pediatric patients and late-onset lupus patients tend to be more severely affected 
(Pons-Estel et al., 2010, Abu-Shakra et al., 2004).  
Survival in patients with SLE has improved over the last decades. Since the 1950’s, the 
estimated 5-year survival of SLE patients in developed countries rose from <50% to 
>95% and similar increases were seen in 10-year survival (Borchers et al., 2004). 
Currently the approximate 5-, 10-, and 15-year survival rates are 96%, 93%, and 76%, 
respectively (Doria et al., 2006). 
Lupus patients have a 3 to 5 times higher mortality compared with the general 
population (Abu-Shakra et al., 2004). Age at onset, sex and race are associated with 
different mortality rates (Bernatsky et al., 2006).  Most notably the proportionate 
mortality from vascular disease, particularly accelerated atherosclerosis increased 
dramatically in SLE patients (Stahl-Hallengren et al., 2000, Borchers et al., 2004). 
In 1976 Urowitz et al. described the bimodal pattern of mortality in SLE with an early 
phase due to renal and central nervous system (CNS) involvement and a late phase due 
to complications of the disease or treatment (Urowitz et al., 1976). 
In the mid 1980’s Rubin, Gladman and Urowitz started to report increased prevalence 
of cardiovascular disease (CVD) in SLE cohorts. Traditional risk factors, such as 
hypertension, metabolic syndrome and cigarette smoking could not entirely explain the 
5 times increased risk to develop atherosclerosis and CVD, even if they were higher in 
SLE patients compared to the general population (Rubin et al., 1985, Gladman and 
Urowitz, 1987). Furthermore, in the group of 35-45 years old women with SLE, the 
risk of developing atherosclerosis was shown to be 50 times higher than in the age and 
sex matched controls (Manzi et al., 1997). 
Several types of vascular lesions can affect diverse organs in SLE and seem to be 
crucial for the majority of clinical manifestations. The most common mechanism of 
vascular involvment is immune complex deposition in the walls of small arteries and 
arterioles. Thrombotic microangiopathic changes can also occur in SLE, especially in 
the presence of anticardiolipin (aCL) and beta 2 glycoprotein antibodies.  
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1.5 AUTOANTIBODIES 
 The complex etiopathogenesis of SLE still remains unsolved. A failure of the 
immune regulatory mechanisms with T-cell dysfunction, B-cell activation and an 
imbalance in the production of cytokines characterize the disease. A consequent 
feature is the overproduction of autoantibodies. 
Autoantibodies are immunoglobulins (Ig) that bind via their combining sites to antigens 
in the same individual or species. In SLE they target nuclear and cytoplasmic 
components of the cell. The presence of antinuclear antibodies (ANA) and complement 
activation are the hallmarks of SLE (Sawalha and Harley, 2004). More than 100 
antibodies are described in SLE, but only a few have clinical relevance: ANA, anti 
double stranded DNA antibodies (anti ds-DNA), anti-Smith antibodies (anti-Sm), anti 
ribonucleoprotein antibodies (anti RNP), Sjögren`s syndrome antibodies A and B (anti-
SSA, anti-SSB) and antiphospholipid antibodies (aPL). The presence of one or more of 
these serologic markers is considered a criterion for SLE diagnosis. 
Natural antibodies (Nab) are secreted mostly by B1-cells in the peritoneum and 
mucosal sites, as well as by marginal zone B cells. They are present in individuals 
without apparent immunization and bind to a variety of microbial polysaccharides and 
lipids. They are predominantly of the IgM isotype (Boes, 2000). IgM antibodies reflect 
a primary immune response, are pentavalent and usually of low affinity.   
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2 ATHEROSCLEROSIS 
Atherosclerosis is a pathologic process in the blood vessels which can lead to CVD. It 
consists of accumulation of foam cells in the arterial wall and atherosclerotic plaque 
formation. Plaques that are unstable, vulnerable and prone to rupture induce thrombus 
formation in the lumen of the artery by exposing thrombogenic material to blood 
circulation. CVD is the most common cause of mortality in developed countries. 
Risk factors, such as age, male gender, smoking, hypertension, diabetes, abdominal 
obesity, hypercholesterolemia and psychosocial factors can statistically explain 90% of 
CVD (Yusuf et al., 2004). In the last decade other risk factors for CVD started to 
receive clinical attention: homocysteinemia, hypertriglyceridemia, low levels of HDL, 
insulin resistance, high levels of CRP and apoB/apoA1 and low levels of natural 
antibodies. The European Society of Cardiology guidelines on CVD prevention, 
published in 2007, address these factors and markers (Graham et al., 2007). Already in 
2003 The European Society of Cardiology developed SCORE (Systematic COronary 
Risk Evaluation) as an instrument for evaluation of the total fatal risk due to CVD 
(Conroy et al., 2003).  
 
2.1 ENDOTHELIUM 
The wall of large arteries consists of 3 layers: intima, media and adventitia. The internal 
layer – intima - comes in direct contact with the blood and its forces. That includes a 
thin lining of endothelial cells (EC), a sub-endothelial layer of connective tissue and an 
internal elastic membrane. Tunica media consists of smooth muscle cells and collagen 
fibres. Adventitia, the outer layer contains fibroblasts, collagen and elastic fibres. 
The endothelium, focus of many studies, is considered the main regulator of the 
vascular homeostasis. It maintains the balance between vasodilation and 
vasoconstriction by secreting vasoactive substances (Davignon and Ganz, 2004). The 
healthy endothelium is both anticoagulant and antithrombotic. EC produce nitric oxide 
(NO), which is a major vasodilator, and inhibit the proliferation of the smooth cells and 
the interaction between circulating blood cells and the arterial wall. EC produce 
prostacyclin (PGI2) which inhibits platelet aggregation, as well as endothelin and 
angiotensin, which are potent vasoconstrictors (Luscher and Barton, 1997, Deanfield et 
al., 2007). Endothelium damage and the factors which inhibit NO production disturb 
the balance between vasodilation and vasoconstriction and initiate a number of events 
that promote atherosclerosis. 
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Altered NO production by EC is considered the hallmark of endothelial dysfunction 
and a precursor of atherosclerosis. NO is produced in EC from its precursor L-arginine 
via enzymatic action of endothelial NO-synthase (e-NOS). Shear stress increases the 
expression of e-NOS whereas statins increase the availability of e-NOS (John et al., 
1998). Asymmetric dymethylarginin (ADMA) inhibits NO production (Cooke, 2000). 
NO prevents oxidation of LDL (Rubbo et al., 2002).  
 
2.2 LIPIDS 
In the early 1950’s J.W. Gofman recognized the importance of lipids and lipoproteins 
in atherosclerosis (Gofman and Lindgren, 1950). More than twenty years later, J.L. 
Goldstein and co-workers discovered the scavenger receptor and described its role in 
atherosclerosis (Goldstein et al., 1979). Meanwhile, the research on lipid lowering 
drugs in the 1990’s led to the broad use of statins in clinical practice. Since then, the 
mortality in CVD declined by 40%, but it is still the major cause of mortality in the 
industrialised countries (Bjorck et al., 2009). 
Cholesterol and triglycerides (TG) are transported in the blood as lipoproteins: very low 
density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density 
lipoprotein (LDL), high density lipoprotein (HDL) and chylomicrons. The first three 
have on the surface an apoB-protein and they are atherogenic. HDL has apoA1 on its 
surface and it is anti-atherogenic, transports the cholesterol to the liver and has anti-
inflammatory and vasodilatatory effects (Walldius and Jungner, 2006). The mature 
chylomicron has apoA; -B; -C and -E on its surface. Some LDL particles from the 
blood enter the endothelium, get oxidized to oxLDL, which is recognized and taken up 
by macrophages. By quantifying apoB an indirect measure for potential atherogenic 
particles is obtained. Meanwhile, the apoA1 level reflects the anti-atherogenic HDL 
particles. Higher apoB/apoA1 ratio is considered a risk factor for CVD development 
(Walldius and Jungner, 2006). For SLE patients however, this ratio has little predictive 
value since their lipid profile is different (Svenungsson et al., 2003). 
 
2.3  ATHEROSCLEROSIS AS AN INFLAMMATORY DISEASE 
During the 1980’s and at the beginning of the 1990’s the association between 
inflammatory variables/markers and atherosclerosis was first reported. Since then, the 
inflammatory nature of atherosclerosis was recognized and described (Ross, 1999, 
Hansson, 2005). The formation of fatty streaks under the endothelium starts during 
childhood. Some streaks disappear and others transform into atherosclerotic plaques, 
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but the exact mechanism of these changes is not fully understood. There is evidence 
that cytokines, such as interferon gamma (IFN-γ), tumor necrosis factor (TNF), 
interleukin (IL) 1 and IL 6, some produced by activated CD4+ T-cells, are involved in 
this process. Once the plaque is formed, matrix metalloproteinases (MMP) and cysteine 
protease contribute to the rupture of the fibrous cap and thrombus formation, with 
consequent partial or total obliteration of the blood vessel. 
Shear stress, determined by blood and plasma viscosity, hematocrit and wall flow 
velocity gradient, activates the endothelial wall of the large and medium arteries and 
regulates the production of NO in vascular wall (Hightower et al., 2011). NO 
bioavailability regulates the contractility of the blood vessels (Forstermann, 2010). 
EC produce leukocyte adhesion molecules, which stimulate monocytes to migrate from 
the blood to the blood vessel wall where they transform into macrophages. Also LDL 
accumulates in the vessel wall and oxidizes to oxLDL and is incorporated into the 
macrophages. Further, activated CD4+ T-cells, which produce IFN-γ, TNF and IL-1, 
are implicated. CD8+ T-cells present in the plaque can be activated by other antigens 
such as viruses and have a regulatory, anti-atherosclerotic role, but can also contribute 
to aneurysm formation by producing elastolytic enzymes (Binder and Silverman, 
2005). 
The B-cells present in the plaque are considered to have anti-atherosclerotic role by 
secreting antibodies against: oxLDL, apoptotic cells and Streptococcus like species. 
These antibodies bind to phosphorylcholine (PC) on respective surfaces and facilitate 
the clearance of these structures from the blood vessel wall (Caligiuri et al., 2003). 
These antibodies, so called natural antibodies (Nab), are secreted by B1 cells and 
marginal zone B-cells in the spleen and are both IgG but mainly IgM antibodies 
(Baumgarth et al., 1999). They arise spontaneously in the perinatal period and have an 
important role in immediate host defense (Chou et al., 2008). Because of their broad 
specificity and low affinity (especially IgM) they are presumed to have an important 
role in the prevention of the autoimmune reactions and in the clearance of immune 
complexes (Shoenfeld et al., 2004).  
In atherosclerosis oxLDL presents a PC epitope that Nab against PC can bind to, thus 
blocking the incorporation of oxLDL into the macrophage and in this way stopping the 
development of atheromathosis (de Faire et al., 2010).  
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3 CARDIOVASCULAR DISEASE AND SLE 
CVD is a consequence of atherosclerosis. It includes coronary artery disease, 
manifested as acute myocardial infarction (AMI) or angina pectoris, cerebral artery 
disease, manifested as transient ischemic attack (TIA) or stroke and peripheral artery 
disease manifested as claudicatio or peripheral ischemia. 
The first reports of the bimodal pattern of morbidity in SLE came in 1976 from  
Urowitz and co-workers (Urowitz et al., 1976), and were later followed by studies from 
Gladman (Gladman and Urowitz, 1987) and Petri (Petri et al., 1992). The latter 
described a cohort of SLE patients, with an average age of 38.3 years, in whom the 
incidence of Coronary Artery Disease (CAD) was 8%! In 1997 Manzi and co-workers 
compared the incidence of CAD between a group of 498 women with SLE and 2208 
women participating in the Framingham study (Manzi et al., 1997). The authors 
reported a 50 times increase in the risk of AMI in SLE patients in the 35-44 year old 
age group. 
Since atherosclerosis is a chronic inflammatory disease and SLE is a multiorgan 
inflammatory disease with increased rate of CVD, many researchers have in the last 10 
years focused on studying the atherosclerotic process in SLE, with the hope of 
discovering the mechanisms of this comorbidity. Generally, the studies have reported 
increased plaque frequency and increased CVD incidence in the SLE patients. 
Similarly significantly increased IMT as well as endothelial dysfunction, measured by 
flow mediated dilation (FMD) have also been reported in SLE (Tyrrell et al., 2010). 
Selection bias, study design and the measurement technique used could have influenced 
the outcomes of these studies. 
Hypertension, diabetes mellitus, smoking, dyslipidemia and male gender are widely 
recognized risk factors for CVD development. However, these factors alone cannot 
fully account for the atherosclerotic process in SLE. Other factors, first described by 
Petri (Petri et al., 1992), such as the age at SLE diagnosis, long disease duration and the 
duration of prednisolone treatment, are currently accepted as significant CVD risk 
factors in SLE. The importance of these factors for the course of the CVD in women 
diagnosed with SLE was later confirmed. Thus, Svenungsson et  al. reported in 2001 a 
significant association between CVD in SLE and circulating oxLDL, high levels of 
triglycerides (TG), low levels of HDL and raised alpha 1-antitrypsin and homocysteine 
(Svenungsson et al., 2001). Doria and co-workers found in 2003 that cumulative doses 
of prednisolone are also important (Doria et al., 2003). Selzer et al. noted in 2004 that a 
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higher level of CRP is associated with increased IMT (Selzer et al., 2004). Frostegård 
concluded in 2005 that a combination of traditional and nontraditional risk factors (e.g. 
inflammation, antiphospholipid antibodies (aPLs), and lipid oxidation) contribute to 
CVD in autoimmune diseases (Frostegard, 2005). Hansson speculated in 2005 that high 
levels of CRP are more likely a consequence of increased IL6, then a direct marker of 
atherosclerosis progress (Hansson, 2005). Later studies demonstrated that only in SLE, 
CRP has a direct pathologic pattern (Barnes et al., 2005).  
Similarly, age, systolic blood pressure and disease duration are important factors for 
increased IMT, as described by Bhatt et al. for an Asian Indian SLE cohort  (Bhatt et 
al., 2006). De Leeuw found in 2006 that inflammatory endothelial markers, such as 
vascular cell adhesion molecule (VCAM) 1, MMP 3, von Willebrand factor, were all 
significantly higher in SLE patients than in controls. However, in a multivariate 
analysis age and SCORE remained the only independent predictors for increased IMT 
in SLE patients (de Leeuw et al., 2006).  
Rho et al. described in 2008 that higher concentrations of adhesion molecules (E-
selectin, VCAM, inter-cellular adhesion molecule (ICAM)) and TNF-alpha are 
associated with coronary atherosclerosis in SLE, independent of the Framingham risk 
score (Rho et al., 2008). The same year Svenungsson et al. reported that high levels of 
sVCAM-1, associated with systemic TNF-alpha activity, were identified as a novel 
discriminator for SLE-related CVD (Svenungsson et al., 2008). Su and co-workers 
reported that low levels of IgM anti PC were associated with the development of 
CVD in the same cohort (Su et al., 2008). 
There is no strong evidence to link disease modifying anti rheumatic drugs with 
development of CVD.  For example, for chloroquine, which lowers the concentration of 
circulating lipids, the association with CVD development is poor (Sachet et al., 2007, 
Becker-Merok and Nossent, 2009) 
The use of statins in SLE patients did not significantly affect the incidence of CVD 
events in a randomized controlled study over two years. The anti-inflammatory effect 
of statins observed in the general population has not been replicated in SLE (Petri et al., 
2011) 
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4 AIMS 
 
 To study atherosclerosis in SLE patients, including plaque vulnerability, as 
compared to control subjects. 
 
 To study traditional and novel risk factors, including the role of anti-PC, in 
relation to atherosclerosis and CVD, in patients with SLE.  
 
 To study microvascular reactivity in SLE patients compared with controls, in 
relation to atherosclerosis and CVD. 
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5 PATIENTS AND METHODS 
5.1 PATIENTS 
All 160 patients with SLE aged between 18 and 70 years, under observation and 
treatment at Karolinska University Hospital Huddinge, where invited in 2006 to 
participate in the study called SLEVIC (SLE vascular impact cohort). Age and sex 
matched controls, free of systemic inflammatory diseases, recruited from the 
Population Register of the South Stockholm catchment area were asked to participate in 
the study as controls. Finally, at the end of 2007, 118 patients and 122 controls had 
been included in the study. Four of these patients did not fulfil the revised ACR criteria 
for SLE and were later excluded from the analyses.  
All 114 patients and 122 controls gave their written consent to participate in the study. 
The study was approved by the research ethics committee at Karolinska Institutet. 
 
The first study (Study I) included all 114 patients and 122 controls enrolled. The 
demographic and baseline characteristics of the groups are presented below (Table 2). 
 
Table 2. Demographic and baseline characteristics of the study groups – study I 
Characteristics 
SLE Patients 
(n=114) 
Controls 
(n=122) 
P level 
Age, years 48±13 49±13 NS 
Male gender 12.3% (n=14) 10.6% (n=13) NS 
Current smokers 14.0% (n=16) 15.5% (n=19) NS 
BMI, kg/m
2 
24.9 (21-28) 24.7 (22.5-27.8) NS 
n = number; NS = non significant 
 
The SLE-patients had a disease duration mean (SD) 12±10 years and mean (range) 
SLE activity measure, SLAM, 6 (0-20), SLE disease activity index, SLEDAI 2 (0-27), 
and Systemic Lupus International Collaborating Clinics damage index, SLICC 1 (0-8). 
 
In the second study (Study II) 84 patients and 81 sex and age matched controls from the 
same cohort were included. Demographic and baseline characteristics of the groups are 
presented in Table 3. 
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Table 3. Demographic and baseline characteristics of the study groups – study II  
Characteristics 
SLE patients 
(n=84) 
Controls 
(n=81) 
P level 
Age, years 47±14 51±13 NS 
Male gender 17% (n=14) 14% (n=11) NS 
Current smokers 9.52 (n=8) 14.29 (n=12) NS 
BMI, kg/m
2
 25.14±4.54 25.68±5.62 NS 
n = number; NS = non significant 
 
The SLE disease duration was of mean (range) 8 years (0-40), SLAM 6 (0-18), 
SLEDAI 2 (0-27) and SLICC 1 (0-8). 
 
5.2 METHODS 
5.2.1 General facts 
Blood samples were collected between 7:00-10:00 AM, after 12 hours of fasting. The 
patients and controls had the weight, height and waist circumference measured. The 
body mass index (BMI) was calculated for the study participants. All subjects met with 
a medical doctor, who obtained a CVD focused medical history and proceeded with 
clinical investigation. Subsequently they, except for 3 patients, were investigated by 
Doppler carotid ultrasonography to determine IMT, cIMa and plaque presence. For the 
SLE patients SLAM; SLEDAI; SLICC were calculated (Liang et al., 1988, Bombardier 
et al., 1992, Gladman et al., 1996). 
Medication: We calculated the doses of glucocorticoids (GC) taken by the patients up 
to the time of inclusion in the study. We looked at the total intake, last year’s intake, as 
well as current and past dose per month, when available in the patient’s chart (Table 4). 
 
Table 4. Glucocortiocoids treatment characteristics for the SLE patients  
Characteristic Study I Study II 
GC total intake (gram) 13.18 (4.53-29.72) 13 (4.3-27.37) 
GC last year intake (gram) 1.42±1.7 1.45±1.53 
GC total intake/month  
(gram) 
0.21 (0.15-0.30) 0.21 (0.15-0.30) 
GC last year intake/month 
(gram) 
0.12 (0-0.22) 0.11 (0-0.19) 
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The biochemical variables were determined by standard laboratory methods. Serum and 
cells were separately prepared before storage at -80°C. 
Immunological analyses of aCL antibodies and beta 2 glycoprotein antibodies were run 
by Karolinska Immmunlaboratory, Solna using an enzyme-linked immunosorbent 
assay (ELISA). 
Anti PC IgM were determined using a commercial ELISA kit (Athera CVDefine-TM, 
Stockholm, Sweden) as described by the manufacturers. Anti PC IgG were also 
determined using the CVDefine kit, but the secondary antibody was switched to detect 
IgG (i.e. Horseradish Peroxidase – goat - antihuman IgG, Invitrogen, Sweden). 
Insulin resistance was determined using the homeostasis model assessment of insulin 
resistance (HOMA-IR) according to the following formula: HOMA-IR = fasting insulin 
(µU/ml)*fasting glucose (mmol/L)/22.5. 
 
5.2.2 Carotid ultrasound 
The right and left carotid arteries were examined with a duplex scanner (Sequoia, 
Siemens Acuson, Mountain View, CA, USA) using a 6 MHz linear array transducer. 
The far wall of the common carotid artery (CCA), 0.5 to 1.0 cm proximal to the 
beginning of the carotid bulb, was used for measurements of the IMT and lumen 
diameter. The IMT was defined as the distance between the leading edge of the lumen-
intima echo and the leading edge of the media-adventitia echo. The lumen diameter 
was defined as the distance between the leading edge of the intima-lumen echo of the 
near wall and the leading edge of the lumen-intima echo of the far wall. The mean 
values of the IMT and lumen diameter within the 10 mm long section were calculated. 
When a plaque was observed in the region of the CCA measurements, the IMT was not 
measured.  
Carotid plaque was defined as a localized intima-media thickening of greater than 1 
mm and at least a 100% increase in thickness compared with adjacent wall segments. 
We screened for plaque in the common, internal and external carotid arteries. Plaque 
occurrence was scored as the absence of plaque, the presence of unilateral plaque, and 
the presence of bilateral plaque. Plaque morphology in terms of echogenicity was 
assessed using a modified version of Gray-Weale classification (Gray-Weale et al., 
1988) and graded from 1 to 4 as echolucent, predominantly echolucent, predominantly 
echogenic and echogenic. Echolucency was defined with the arterial lumen as a 
reference and echogenicity with the far wall media-adventitia echo as a reference. 
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To compensate for the stretching effect of arterial distension on the wall thickness 
(secondary to increased arterial pressure), the cross-sectional intima-media area was 
calculated using the formula: Cross sectional intima media area = 3.14*(lumen 
diameter/2 + IMT)
 2
- (lumen diameter/2)
2
. This calculated intima-media area (cIMa), 
but not the IMT, has been shown to be unaffected by variations in artery distension 
secondary to changes in blood pressure (Jogestrand et al., 1995). 
 
5.2.3 Laser Doppler fluxmetry and ionthophoresis 
The studies were conducted in a dedicated microvascular measurement facility, with 
stable ambient temperature (23±1°C) and with no detectable circulating draught. The 
subjects were lying supine with both arms comfortably besides the body. Prior to the 
start of flux recordings, subjects were acclimated to room temperature for 20 min. 
Acetylcholine (ACh) iontophoresis. Our protocol was based on the protocol previously 
described by Hansell and co-workers (Hansell et al., 2004). An iontophoresis electrode 
chamber was attached on the dorsal side of the non-dominant hand between fingers 1 
and 2, using a double-sided adhesive disc. The chamber held the laser probe vertically 
enabling the skin perfusion to be measured directly over the site of drug application. An 
indifferent electrode was attached on the forearm at 15 cm distance from the probe. The 
chamber was filled with 1% ACh, which induces endothelium-dependent dilation and 
smooth muscle–mediated constriction. A PeriIont System 480-1 battery-powered 
iontophoresis controller provided the direct current for iontophoresis. A thermostatic 
probe holder helped to stabilise the skin temperature at 32°C. Iontophoresis allows 
charged substances to cross the skin by means of a small electrical current. After a 
baseline recording of 2 minutes, ACh was delivered using an anodal current of 0.1 mA 
for 20 seconds with iontophoretic stimulation, repeated six times at 60 seconds interval 
between doses. The flux response to ACh was continuously recorded for 5 minutes 
following the final sixth stimulation dose. A Laser Doppler (LD) instrument (Periflux 
4001TM, wavelength 780 nm, Stockholm, Sweden) was used to measure perfusion 
changes during vascular provocations (Perimed AB, Stockholm, Sweden). The LD 
signal is proportional to the number and velocity of moving blood cells in illuminated 
superficial skin microvessels. The LD output is semi quantitative and expressed in 
perfusion units of output voltage. 
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5.3 STATISTICS 
Variables were dichotomized or considered as continuous variables as indicated. 
Some variables were logarithmically transformed to minimize the skewness. We have 
calculated percentiles based on distributions in the whole study group. Age, gender 
and geographic area were matched through the design of the study. Taken into 
account the normality of the distribution, comparisons between groups were made 
using the Mann-Whitney U-test or Student’s t-test. 
In order to establish the association between potential risk factors for atherosclerosis 
and atherosclerotic plaque, logistic regression was applied with adjustment for 
covariates. Spearman correlation coefficient test was used for univariate correlations 
between continuous variables in study II, as well as linear general models and analysis 
of covariance. 
Differences were considered statistically significant if the p-value was less than 0.05.  
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6 RESULTS 
6.1 PAPER I 
As shown in Table 5, the patient group had increased prevalence of hypertension (p < 
0.001), higher levels of TG (p < 0.01), CRP (p < 0.001), HOMA-IR (p < 0.05) and 
apoE (p< 0.01) than the control group. Low IgM anti-PC levels occurred more often in 
SLE patients (lowest tertile; p < 0.01 anti-PC determinations available for 111 SLE-
cases and 118 controls). We also found lower LDL levels (p < 0.05), as previously 
described. There were no significant differences regarding smoking habits, diabetes 
(few cases), total cholesterol, HDL, apoB/apoA levels or BMI. 
 
Table 5. Clinical and laboratory characteristics of patient and controls 
Characteristic 
Cases 
(n=114) 
Controls 
(n=122) 
P level 
Presence of diabetes 5.26% (n=6) 2.45% (n=3) NS 
    
Presence of 
hypertension % (n) 
57.89%  
(n = 66) 
26.22%  
(n = 32) 
<0.001 
    
Total cholesterol 
(mmol/L) 
4.7±1.1 4.8±1.0 NS 
    
LDL (mmol/L) 2.5±0.88 2.8±0.80 <0.05 
HDL(mmol/L) 1.6 (1.3-1.8) 1.6 (1.3-1.9) NS 
Triglicerides (mmol/L) 0.99 (0.7-1.4) 0.78 (0.55-1.10) <0.01 
CRP (mg/L) 4.44 (0.8-4.8) 2.04 (0.5-2.5) <0.001 
ApoE (mg/L) 42.69±14.7 38.84±12.05 <0.05 
ApoB/ApoA1, ratio 0.55 (0.50-0.70) 0.60 (0.50-0.70) NS 
BMI (kg/m
2
) 24.89  
(20.96-27.85) 
24.67 
(22.41-27.82) 
NS 
    
HOMA – IR 1.34 (0.80-1.96) 1.05 (0.69-1.48) <0.05 
IgM antiPC, 
lowest tertile 
30.70%  
(n = 35) 
16.39%  
(n = 20) 
<0.01 
    
IgG antiPC (U/ml) 9.31 (5.42-14.72) 7.45 (4.62-11.83) <0.05 
n = number; NS = non significant 
 
As shown in Table 6, IMT and cIMa did not differ between groups, whereas a 
difference between the groups in occurrence of atherosclerotic plaques (p < 0.05) was 
found. In addition, left-sided echolucent plaques were more prevalent in the SLE 
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patients as compared to controls (p < 0.05), but there was no significant difference in 
echolucent plaque on the right side. CVD occurrence was increased in SLE patients (p 
< 0.01) when CVD was defined as a history of cerebrovascular events, AMI, coronary 
artery by-pass graft (CABG), heart valve prosthesis/impairment, peripheral arterial 
surgery or claudicatio. 
 
Table 6. Carotid measurements in SLE-patients and controls 
Measure Cases Controls P level 
IMT R (mm) 0.60±0.13 0.62±0.13 NS 
IMT L (mm) 0.59 (0.50-0.71) 0.60 (0.52-0.70) NS 
cIMarea R (mm
2
) 11.39 (9.60-14.34) 11.90 (9.93-14.01) NS 
cIMarea L (mm
2
) 11.81 (9.41-13.43) 11.64 (9.88-13.83) NS 
Plaque presence 42.98% (n=49) 30.32% (n=37) <0.05 
Low-echogenic plaques 
(grade 1) left carotid artery  
n=25 n=13 <0.05 
Low-echogenic plaques 
(grade 1) right carotid artery 
n=19 n=18 NS 
CVD 21.92% (n=25) 2.45% (n=3) <0.001 
n = number; NS = non significant; R = right side; L = left side 
 
We further compared the SLE-patients with and without plaques. In univariate 
analyses, age, SLE duration, hypertension, fasting glucose-level but not HOMA-IR, 
LDL-cholesterol, total cholesterol, apoB/apoA1 ratio, BMI, and IgM anti PC-levels 
were significantly different between SLE-patients with and without plaques. The total 
GC intake was not associated with atherosclerotic plaques (Table 7). 
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Table 7. Characteristics of SLE patients with and without atherosclerotic plaques 
             SLE patients  
With plaque 
(n=49) 
Without plaque 
(n=62) 
P level 
Age, years 55.79±9.23 41.7±12.76 <0.001 
Average disease duration (years) 14.00 9.82 <0.05 
Current smokers % (n) 7.2% (n=8) 6.3% (n=7) NS 
Presence of hypertension % (n) 31.5% (n=35) 27% (n=30) <0.05 
Presence of diabetes % (n) 4.5% (n=5) 0.9% (n=1) <0.05 
Glucose (mmol/L) 4.70 (4.30-5.00) 4.35 (3.90-4.70) <0.01 
LDL (mmol/L) 2.87±1.05 2.28±0.66 <0.01 
Cholesterol (mmol/L) 5.05±1.26 4.35±0.98 <0.01 
ApoB/ApoA1, 0.60 (0.50-0.80) 0.50 (0.45-0.60) <0.01 
Triglycerides (mmol/L) 1.00 (0.74-1.50) 0.94 (0.61-1.30) 0.065 
BMI (kg/m2) 25.95 
(22.28-28.41) 
24.16 
(20.08-26.84) 
<0.05 
Cumulative lifetime GC dose/year 
(gram/year) 
2.49  
(1.75-3.68) 
2.59  
(1.87-3.49) 
NS 
Glucocorticoid last year (gram) 0.9 (0-2.19) 1.8 (0.07-2.70) NS 
Chloroquin/hydroxychlorochine 42.85% (n=21) 54.83% (n=34) NS 
IgM anti PC 48.75  
(25.79-104.78) 
85.94  
(50.02-231.52) 
<0.001 
IgM antiPC<=33
th
 percentile (%) 57.45 28.81 <0.01 
n = number; NS= non significant; 25
th
 and 75
th
 quartile presented between brackets  
 
In a multivariate analysis only age, hyperlipidemia (LDL  3 mmol/L) and IgM anti-PC 
(lowest tertile) remained significant and independently associated with plaque 
occurrence. If patients with previous CVD were excluded, the associations between low 
anti-PC and plaque prevalence remained significant (OR 4.4; CI 1.34 to 14.88; p < 
0.05). 
Conclusions: Taken together, our data indicate that atherosclerotic plaques, but not 
general atherosclerosis as indicated by IMT measurements, were more prevalent in 
SLE patients when compared to controls. Furthermore, vulnerable atherosclerotic 
plaques were more common in SLE. Age, LDL and low levels of IgM anti-PC were 
independently associated with the prevalence of atherosclerotic plaques in SLE. 
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6.2 PAPER II 
In study II the smaller groups of 84 patients and 81 controls had nearly the same 
characteristics as in the first study. The frequency of hypertension and CVD was 
significantly higher in SLE patients compared with controls and there were also 
differences in HOMA-IR, CRP, ESR and homocysteine levels (Table 8). 
Concerning the lipid profile, the patients had significantly lower cholesterol and LDL 
but higher TG. 
 
Table 8. Clinical and disease characteristics for patients and controls in study II 
Characteristic 
Case 
n = 84 
Controls 
n = 81 
P level 
Age, years 47±14 51±13 NS 
Sex (women) 83% (n=70) 86% (n=70)  
Present smokers n=8 n=12 NS 
Ever smokers n=43 n=46 NS 
Pack years 7.64±12.53 6.73±9.08 NS 
Hypertension 60% (n=50) 24% (n=10) <0.001 
CVD 19% (n=16) 2% (n=2) <0.001 
HOMA-IR 1.56±0.96 1.26±1.07 0.056 
CRP, mg/L 4.55±6.29 1.96±2.52 <0.001 
ESR, mm/h 23±17 9±5 <0.001 
apoB/apoA1 0.59±0.22 0.65±0.33 NS 
TG, mmol/L 1.08±0.64 0.90±0.46 <0.05 
Cholesterol, mmol/L 4.63±1.14 4.97±1.01 <0.05 
HDL, mmol/L 1.60±0.45 1.72±0.59 NS 
LDL, mmol/L 2.53±0.87 2.91±0.82 <0.01 
Homocysteine, µmol/L 13.42±5.47 11.57±4.80 <0.01 
n = number; NS= non significant 
 
6.2.1 Carotid measurements  
There were no differences between IMT on either sites (right and left) between patients 
and controls. In all, 40% of the patients and 30% of controls had carotid plaques, p = 
0.004 (when controlled for age). 
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6.2.2 Laser Doppler Fluxmetry (LDF) 
Neither basal skin perfusion nor maximal skin perfusion response (MSPR) to 
iontophoresis of ACh was significantly different between patients and controls, when 
measured in perfusion units. The percentage change, defined as (MSPR-Basal 
flux)/Basal flux * 100) was found to be significantly higher in the patient group (p < 
0.05). 
We further analyzed if MSPR differed between the subgroups of SLE patients. It was 
obvious that patients treated for hypertension and those with CVD had significantly 
lower MSPR than those not treated for hypertension and those without CVD, 
respectively (Table 9). 
No correlation was found between MSPR and the measures of disease activity and 
damage (SLAM, SLEDAI and SLICC). 
We further checked whether differences in microcirculation existed between patients 
treated with different antihypertensive agents and those not treated. No significant 
differences in MSPR were found between patients on angiotensin converting enzyme 
(ACE) inhibitors vs. those not on ACE inhibitors, (89 vs. 73 PU; p = 0.378), nor for 
those on angiotensin receptor-blockers (ARB) vs. those not (87 vs. 24 PU; p = 0.131), 
nor between those on beta-blockers vs. those not taking them (89 vs. 61 PU; p = 0.194) 
and nor in those on Ca-antagonist vs. those not on the medication (87 vs 71 PU; p = 
0.48).  
No significant differences were found regarding MSPR values between patients treated 
or not treated with chloroquine (p = 0.623), or those on or off GC (p = 0.273). 
Although smoking status (actual and previous) had no significant effect on MSPR, we 
found negative correlations between pack years and MSPR (Spearman r = -0.234, p < 
0.05), as well as percentage response (r = -0.251, p < 0.05).  
The percentage response to ACh correlated negatively with IMT left (r = -0.336, p < 
0.01), whereas the other LDF measures did not significantly correlate with IMT. 
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 Table 9. Maximum skin perfusion response with LDF for 84 SLE patients, when 
separated into presence = 1, or not = 0 of disease manifestations and co-morbidities 
 
MSPR = Maximum skin perfusion response; NS = non significant; 
PU = perfusion units 
 
Conclusions: Skin microvascular endothelial function is associated with CVD, but not 
with early signs of atherosclerosis in SLE-patients. The endothelial function is not 
different in SLE-patients as compared to controls. 
 
                                                 
1
 LDL ≥ 3mmol/L and/or lipid lowering treatment 
 
 
Number MSPR (PU) P level 
Skin  0 15 95.77±54.88 NS 
 
1 69 82.37±73.51 
 
Raynaud               0 45 90.76±76.20 NS 
                           1 39 77.84±63.43 
 
Nephritis                0 54 83.77±78.03 NS 
                              1 30 86.54±55.41 
 
Hyperlipidemia
1
          0 57 90.41±69.63 NS 
                              1 27 72.83±71.99 
 
Hypertension         0 34 99.77±79.50 NS 
                               1 50 74.56±62.34 
 
HT treatment 0 48 99.31±79.56 <0.05 
                               1 36 65.37±50.89 
 
CVD total 0 68 92.53±73.14 <0.05 
 
1 16 51.57±46.10 
 
Plaque 0 48 90.05±69.76 NS 
 
1 34 80.35±72.93 
 
Present smokers    0 76 87.38±72.09 NS 
                                1 8 59.89±48.71 
 
Ever smokers         0 41 94.16±66.78 NS 
                                1 43 75.80±73.43 
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7 DISCUSSION 
The patients with SLE had an increased number of carotid atherosclerotic plaques, as 
compared to sex- and age-matched controls from the same geographic area. Common 
carotid IMT and cIMa did not differ compared with controls. 
The observation of increased occurrence of atherosclerotic plaques is in accordance 
with other observational and/or prospective studies (Doria et al., 2003, Manzi et al., 
1999) and controlled studies (Roman et al., 2003, Asanuma et al., 2003, Svenungsson 
et al., 2001), where increased atherosclerosis has been reported as a feature of SLE. 
The finding that plaque occurrence but not IMT or cIMa was increased in SLE is in 
line with previous publications (Roman et al., 2003, Svenungsson et al., 2001). 
Furthermore, in our present study patients with SLE had echolucent plaques more 
often than controls in the left carotid artery. Carotid echolucent plaques are 
considered to represent more vulnerable atherosclerotic lesions than echogenic 
plaques (Kwee et al., 2008). Thus, individuals with carotid stenosis and echolucent 
plaques were reported to have an increased risk of stroke and cerebrovascular events 
compared with individuals with stenosis and more echogenic plaques (Mathiesen et 
al., 2001). 
In the present study nine SLE patients had reported stroke/TIA in medical history, 
compared with one control. The reason for the increased occurrence of echolucent 
plaques on the left but not on the right side in SLE-patients is not clear. One 
explanation might be the difference in gross anatomy of the left and right common 
carotid artery (CCA) which might create different shear stress conditions. Shear stress 
has been shown to be related to both intima-media thickness and echogenecity (Lind 
et al., 2009). 
We found that low levels of natural IgM anti-PC antibodies were more prevalent in 
the SLE-patients group as compared with controls. This correlates with similar 
findings in a nested case-control study, where SLE patients with CVD were compared 
to those without CVD and with controls (Su et al., 2008). We also noted that IgG 
anti-PC were higher in SLE patients than in controls in the present study, which did 
not confirm previous data (Su et al., 2008). However, differences in study design, 
higher mean age, and only female SLE-patients in the Su et al. study, could explain 
the inconsistency. 
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High levels of IgM antiPC were previously associated with decreased prevalence of 
CV events in a group of hypertensive subjects (Su et al., 2006). Furthermore, low 
levels of IgM anti-PC predicted CVD in 60 years old men (de Faire et al., 2010) as 
well as AMI (Gronlund et al., 2009), stroke (Sjoberg et al., 2009) and mortality risk 
in patients on hemodialysis (Carrero et al., 2009). 
In a study from 2006 Faria-Neto reported that passive immunization with monoclonal 
IgM antiPC reduced the vein graft atherosclerosis in apoE-null mice (Faria-Neto et 
al., 2006). In another mouse-model IgM anti-PC were shown to be protective against 
lethal meningococcal infections (Briles et al., 1982). Anti-PC antibodies have anti-
inflammatory properties, inhibiting inflammatory phospholipids such as platelet 
activating factor (Su et al., 2008). Thus, low IgM anti-PC could represent an immune 
deficiency state, predisposing to CVD and inflammatory diseases (SLE included). 
Interestingly, platelet activating factor is a potent pro-inflammatory mediator 
implicated in active SLE (Tetta et al., 1990) but also in a diverse range of other 
human pathologies including shock, ischemia, asthma, CNS and renal disorders. 
Platelet activating factor induces leakage supposed to be mediated by an interaction 
between ROS and NO (Klabunde and Anderson, 2002). 
Furthermore, human anti-PC inhibits the uptake of oxLDL in macrophages, implying 
another non-mutually exclusive possible mechanism by which IgM anti-PC could be 
atheroprotective (de Faire et al., 2010). We hypothesized that this may contribute to 
the low incidence of CVD, in addition to more favorable metabolic and other risk 
factors. Diet factors and exposure to infectious agents, including nematodes and 
parasites may contribute, but the reasons for differences in anti-PC levels among 
cohorts are not well understood (Frostegard et al., 2007). The possibility that diet 
factors contribute to anti-PC levels is supported by recent findings from our group 
showing that for patients with rheumatoid arthritis, a gluten-free vegan diet (Elkan et 
al., 2008) and self-reported Mediteranian diet (Elkan et al., 2009) led to increased 
levels of IgM anti PC.  
Among traditional risk factors, hypertension and increased TG were significantly 
more common in SLE, while smoking was not, which is in line with previous 
publications (Svenungsson et al., 2001). LDL is not known to be commonly raised in 
SLE, and in this study, the frequency of hyperlipidemia was even higher among 
controls. An interesting finding is that HOMA-IR, a measure of insulin resistance, 
was increased in SLE. This confirms findings in a previous report (El Magadmi et al., 
2006) and implies that SLE in general is characterized by early metabolic changes. 
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Within the SLE group, plaque occurrence was independently and positively 
associated with age and LDL and negatively with IgM anti-PC. This finding is in 
accordance with our previous study reporting a negative association between IgM 
anti-PC and atherosclerosis development in hypertensive patients (Su et al., 2006). 
Thus, traditional risk factors in combination with low levels of IgM anti-PC may 
explain the observed increased occurrence of plaques in SLE as seen in study I. 
Cumulative or present doses of prednisolone (or other GC) were not associated with 
the occurrence of atherosclerotic plaques. Prednisolone has been much discussed in 
autoimmune diseases and has often been described as pro-atherogenic due to its 
unfavorable effects on metabolic factors. However, in a recent report on rheumatoid 
arthritis, no association between low-dose prednisolone intake and atherosclerosis 
development was found (Hafstrom et al., 2007). Our present data argue against the 
possibility that prednisolone is proatherogenic in SLE. 
In study II we could not determine any significant difference in endothelial response 
to ACh iontophoresis in microcirculation, measured by LDF, between SLE-patients 
and controls. Our finding is in line with two previous smaller studies which also 
failed to find a difference in microcirculation, in SLE patients as compared to controls 
(Bengtsson et al., 2010, de Leeuw et al., 2008).  
LDF has been analyzed also in other rheumatic diseases, for small patients groups: 
microvascular circulation was impaired in fibromyalgia and systemic sclerosis (Morf 
et al., 2005), also in ankylosing spondylitis (van Eijk et al., 2009) but not in early 
rheumatoid arthritis (van Eijk et al., 2011). 
Previous studies on endothelial function as an early sign of CVD showed a 
correspondence between results obtained using invasive and non-invasive 
measurement methods. Thus, in 1995 Anderson et al. described a positive correlation 
between coronary vasoconstriction, produced by ACh (as a marker of damaged 
endothelium) and impaired FMD in the brachial artery (Anderson et al., 1995). 
Hansell and co-workers later described a correlation between FMD and LDF after 
ACh iontophoresis in healthy individuals (Hansell et al., 2004), though this finding 
was not subsequently confirmed in a later study (Gori et al., 2006).  
ACh is a vasodilator agonist used in studies to stimulate endogen production of NO. 
In the coronary artery ACh may lead to vasoconstriction of the smooth cells 
(Davignon and Ganz, 2004, Ludmer et al., 1986). ACh applied on the skin stimulates 
the production of prostanoids (Berghoff et al., 2002). The cutaneus blood flow 
measured by LDF is regulated by endothelial, neuronal and humoral factors. ACh 
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increases the endothelial production of NO, but the iontophoresis is produced by a 
current which has been reported to stimulate the neuronal mechanisms (Berghoff et 
al., 2002). However, it is unlikely that the low current used herein produce such an 
effect (Hu et al., 1998, Martin et al., 2000). Localization and dimension of the 
iontophores probe may also influence the results of the measurements (Gardner-
Medwin et al., 1997). Using our protocol, unspecific neurogenic vasodilation in 
response to the current used for iontophoretic stimulation is unlikely. Anodal 
iontophoresis must be used for longer periods with higher current strength and more 
concentrated ACh solutions to elicit axon reflexes (Martin et al., 2000).  
The most commonly used method to determine endothelial function is FMD, and 
many if not all studies indicate that by use of this method, an impaired endothelial 
function is implicated in SLE (El Magadmi et al., 2004, Lima et al., 2002, Valdivielso 
et al., 2008, Kiss et al., 2006). However, in other studies, including our own, such a 
difference was not statistically significant (Cypiene et al., 2009, Aizer et al., 2009, 
Svenungsson et al., 2008). Differences in methodology and study design could 
possibly account for opposing results. However, in line with an impaired endothelial 
function in SLE are studies using other techniques, but with similar results (Nienhuis 
et al., 2010). 
In this second study based on smaller sample of the same patient cohort (since not all 
patients were investigated with LDF), the prevalence of plaques was raised among 
SLE patients when we adjusted for age. However, we could not determine an 
association between atherosclerosis measurements and LDF, indicating that 
microvascular dysfunction is not an important correlate of atherosclerosis which 
occurs mainly in large arteries. 
In the SLE group investigated with LDF, previously reported differences between 
patients with and without Raynaud’s disease and smokers or non-smokers, could not 
be confirmed (Bengtsson et al., 2010, de Leeuw et al., 2008). This is possibly related 
to differences in group characteristics between the studies. Furthermore, we could not 
detect any association between medication (including chloroquine) and LDF. 
The response to ACh differed between patients with and without CVD and with or 
without anti-hypertensive medication. In both of these groups a less favorable LDF 
response was documented. This finding indicates that in SLE patients with CVD there 
is a disturbance in the microvasculature. We also found a negative correlation 
between pack years and MRSP, a finding in line with previous reports (de Leeuw et 
al., 2008, Bengtsson et al., 2010). 
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The measurement of blood flow in the microcirculation as a response to ACh 
iontophoresis has the advantage of being an easy to use and non invasive method. 
Therefore it can be used to study ACh response during pregnancy and in newborn 
children. Associations between impaired ACh response, low maternal folate and low 
birth weight have been previously reported (Martin et al., 2000, Martin et al., 2007). 
Similarly, in patients with diabetes a correlation between artery stiffness and impaired 
response to ACh in microvascular bed was previously found (Hu et al., 1998). 
Taken together, our data indicate that the prevalence of atherosclerotic plaques is 
increased in SLE, while IMT did not differ. Furthermore, a novel finding is that 
vulnerable plaques are more common among SLE patients. Low IgM anti-PC was, 
for the first time, determined to be an independent risk factor for prevalence of 
atherosclerotic plaques in SLE, together with age and LDL. Microcirculation as 
determined by iontophoresis did not differ between cases and controls, but was 
associated with CVD among SLE patients.  
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8 SVENSK SAMMANFATTNING 
Senaste åren, i takt med teknologins utveckling och möjligheten att mäta mindre och 
mindre strukturer, har immunologins (läran om immunförsvaret) kunskaperna utvidgats 
avsevärt. Kroppens försvarsmekanismer bedöms vara grund till förekomst av många 
sjukdomar. SLE är en av dem, ett inflammatoriskt tillstånd som kan uttrycka sig i flera 
organ. Kroppens egen försvarsmekanism utvecklar antikroppar mot egna celldelar i 
kroppen. En uppkomst teori till sjukdomen är att immunsystemet aktiveras vid celldöd, 
då kärndelar bland annat exponeras för immunförsvarets celler; detta på grund av att 
antikroppar är riktade mot partiklar i cellens kärna. Man har kunnat identifiera mer än 
100 antikroppar hos patienter med SLE. 
 
Ateroskleros är en sjukdom i kroppens större kärl, på svenska kallad åderförkalkning 
eller åderförfettning. Åderförfettning kan starta redan i barndomen, men tar fart framför 
allt efter 45 års ålder och karakteriseras av plack bildning i större blodkärl. Plack kan 
leda till förträngningar och, under vissa omständigheter, tilltäppning av viktiga kärl och 
avstängning av blod försörjelse i livsviktiga organ som hjärta och hjärna, med 
hjärtinfarkt och hjärninfarkt som följd. Detta är fortfarande främsta orsaken till 
sjuklighet och dödlighet i västvärlden. När man tittar inne i plackens struktur hittar man 
bland annat aktiverade immunförsvarsceller. Denna aktivering och påverkan på 
blodkärl bedöms vara orsak till plackutvecklingen. 
 
Patienter med SLE har mycket ökat risk att utveckla åderförkalkning i jämförelse med 
normal befolkning. För att hitta möjligheter till att blockera eller till och med förhindra 
åderförkalknings utveckling, jämför forskare SLE patienter med ålder och sexmatchade 
friska individer.  
 
Ett problem är att hitta orsaken till att åderförkalkningen startar, en annan är att hitta 
individerna som har tendens till den. Det är också målet med våra två studier. 
 
I vår första studie har vi jämfört 114 SLE patienter med 122 ålders och sex matchade 
individer. Vi har kommit fram till att SLE patienter har mera plaque, mera tendens att 
utveckla hjärtkärlsjukdomar och att låga nivåer av antikroppar mot phosphorylcholine 
(ett ämne som finns naturligt i människans cellmembran) är associerade med 
åderförkalkning. 
 
Med ultraljuds teknik har vi, i vår andra studie, undersökt reaktiviteten i hudens små 
blodkärl, som ett tänkbart mått på kärlsjukdom, efter stimulering med en indirekt 
kärlvidgande substans. Vi hittade dock inga skillnader mellan patienter och kontroller 
beträffande reaktiviteten, men sämre reaktivitet var associerad med redan befintligt 
hjärtkärlsjukdom hos pat. 
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